Blog

The prevalence of epilepsy is approximately 0.5–1.0% worldwide. One-third of affected people have poor seizure control [1]. Some patients with intractable seizures seek surgical interventions, but these treatments are ineffective because of unknown aetiologies [2,3]. Many studies emphasized the role of autoimmunity in epileptogenesis [4]. The latest International League Against Epilepsy aetiology classification recognized autoimmune epilepsy as a distinct entity for the first time [5]. Although immune disorders, such as autoimmune encephalitis and systemic lupus erythematosus show symptoms of seizures, this study exclusively focused on neural antibody-mediated epilepsy/seizure (NAME/S).